Table 1 The characteristics of the included studies in this meta-analysis
Author/year | Abdelrahman 2018 [21] | Abdullatif 2021 [28] | Aquino 2015 [44] | Bernardi 2022 [45] | Fili 2022 [46] | Zemba 2022 [18] |
|---|---|---|---|---|---|---|
Research type | Prospective study | RCT | RCT | Retrospective study | Prospective study | Retrospective study |
Age (mean ± SD) (mTLT / CW-TSCPC) | 67.8 ± 48 / 61.3 ± 38.3 months | 48.6 ± 6.6 / 53 ± 10.6 years | 63.50 (54.75,74) / 66 (55, 72.75) years | 68.9 ± 13.3 / 73.1 ± 15.5 years | 77.77 ± 10.97 years | 55.6 (range, 44‑79) / 58.1 (range, 32‑87) years |
Type of glaucoma | PCG, Aphakia/pseudophakia Aniridia glaucoma, Peter’s anomaly, Microspherophaki, Sturge Weber glaucoma | open-angle glaucoma | POAG, PACG, NVG, Silicone oil, Aphaki, Traumatic glaucoma | POAG, ACG, PEXG, PDG, Aphakic glaucoma, OHT, Others | POAG, PEXG | NVG |
Characteristics of mTLT (power, duration) | 2000 mW, a duty cycle of 31.3%, 100 to 120Â s | 2000 mW, a duty cycle of 31.3%, 200Â s | 2000 mW, a duty cycle of 31.3%, 100Â s | 2000 mW, a duty cycle of 31.3%, 160Â s | 2500 mW, a duty cycle of 31.3%, >160Â s | 2000 mW, a duty cycle of 31.3%, 180Â s |
Characteristics of CW-TSCPC (power, duration) | 1.5 W, 45 s | 1.5–2 W, 40–56 s | 1.5–2 W, 40–56 s | 2 W, 37.5 s | 2–2.3 W, 36 s | 1.25 W, 80–84 s |
No. of eyes (mTLT / CW-TSCPC) | 17 / 28 | 10 / 10 | 24 / 24 | 47 / 150 | 15 / 15 | 24 / 22 |
Duration of follow-up (months) | 6 | 6 | 18 | 12 | 12 | 12 |
Baseline IOP (mmHg, mean ± SD)(mTLT / CW-TSCPC) | 28.3 ± 8.2 / 27.5 ± 6.1 | 18.7 ± 2.9 / 19.8 ± 5.0 | 36.5 (29.5, 56.5) / 35.0 (29.5, 46.5) | 22.0 ± 7.2 / 28.3 ± 12.3 | 17.75 ± 6.92 / 19.13 ± 7.27 | 34.7 ± 10.3 / 36.0 ± 13.2 |
IOP reduction at the last visit (%) (mTLT / CW-TSCPC) | 63 ± 28 / 67 ± 25 | 23.9 ± 6.1 / 31.5 ± 25.3 | - | 31.1 / 43.7 | - | 23.0 / 33.6 |
Success rates at the last visit (%) (mTLT / CW-TSCPC) | 71 / 46 | 60 / 50 | 52 / 30 | 87.5 / 88.6 | 60 / 20 | 33.3 / 54.5 |